间充质基质细胞作为多发性硬化症新型细胞治疗的潜力。
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.
机构信息
National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
出版信息
Immunotherapy. 2012 May;4(5):529-47. doi: 10.2217/imt.12.41.
Abstract
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.
摘要
多发性硬化症（MS）是一种中枢神经系统的炎症性神经退行性疾病，目前只有部分有效的治疗方法。深入研究定义潜在的免疫病理生理学不仅提高了我们对 MS 的认识，也揭示了疾病干预的潜在靶点。间充质基质细胞（MSC）治疗具有调节导致脱髓鞘和轴突损伤的异常免疫反应的潜力，以及修复和恢复受损的中枢神经系统组织和细胞。本文综述了 MS 的病理生理学，并基于作者内在地参与 MS 和 MSC 基础和转化科学研究的经验，为 MSC 治疗领域提供了前沿视角。
相似文献
1
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.间充质基质细胞作为多发性硬化症新型细胞治疗的潜力。
Immunotherapy. 2012 May;4(5):529-47. doi: 10.2217/imt.12.41.
2
Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.间充质干细胞和诱导多能干细胞作为治疗多发性硬化症的方法。
Int J Mol Sci. 2015 Apr 24;16(5):9283-302. doi: 10.3390/ijms16059283.
3
Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.间充质干细胞的免疫调节特性及其在多发性硬化症治疗中的作用。
Cell Immunol. 2015 Feb;293(2):113-21. doi: 10.1016/j.cellimm.2015.01.002. Epub 2015 Jan 10.
4
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.间充质干细胞移植作为多发性硬化症治疗方法的治疗潜力：国际 MSCT 研究组共识报告。
Mult Scler. 2010 Apr;16(4):503-10. doi: 10.1177/1352458509359727. Epub 2010 Jan 19.
5
Mesenchymal stem cells in multiple sclerosis - translation to clinical trials.多发性硬化症中的间充质干细胞——向临床试验的转化
J Med Life. 2015 Jan-Mar;8(1):24-7.
6
The Therapeutic Mechanisms of Mesenchymal Stem Cells in MS-A Review Focusing on Neuroprotective Properties.间充质干细胞治疗多发性硬化症的机制：综述神经保护特性。
Int J Mol Sci. 2024 Jan 23;25(3):1365. doi: 10.3390/ijms25031365.
7
Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.鞘内注射间充质基质细胞源性神经祖细胞治疗多发性硬化症的临床安全性。
Cytotherapy. 2016 Dec;18(12):1476-1482. doi: 10.1016/j.jcyt.2016.08.007. Epub 2016 Oct 7.
8
Multiple sclerosis: a battle between destruction and repair.多发性硬化症：破坏与修复之间的较量。
J Neurochem. 2007 Jan;100(2):295-306. doi: 10.1111/j.1471-4159.2006.04232.x. Epub 2006 Nov 13.
9
Harnessing the therapeutic potential of mesenchymal stem/stromal cell-derived extracellular vesicles as a novel cell-free therapy for animal models of multiple sclerosis.利用间充质干/基质细胞衍生的细胞外囊泡的治疗潜力作为多发性硬化症动物模型的一种新型无细胞疗法。
Exp Neurol. 2024 Mar;373:114674. doi: 10.1016/j.expneurol.2023.114674. Epub 2023 Dec 30.
10
Effects of mesenchymal stem cells transplantation on multiple sclerosis patients.间充质干细胞移植对多发性硬化症患者的影响。
Neuropeptides. 2020 Dec;84:102095. doi: 10.1016/j.npep.2020.102095. Epub 2020 Sep 17.
引用本文的文献
1
Blood-brain barrier disruption: a culprit of cognitive decline?血脑屏障破坏：认知衰退的罪魁祸首？
Fluids Barriers CNS. 2024 Aug 7;21(1):63. doi: 10.1186/s12987-024-00563-3.
2
Decision trees to evaluate the risk of developing multiple sclerosis.用于评估患多发性硬化症风险的决策树。
Front Neuroinform. 2023 Aug 15;17:1248632. doi: 10.3389/fninf.2023.1248632. eCollection 2023.
3
BMSCs Promote Differentiation of Enteric Neural Precursor Cells to Maintain Neuronal Homeostasis in Mice With Enteric Nerve Injury.BMSCs 促进肠神经前体细胞分化以维持肠神经损伤小鼠的神经元稳态。
Cell Mol Gastroenterol Hepatol. 2023;15(2):511-531. doi: 10.1016/j.jcmgh.2022.10.018. Epub 2022 Nov 4.
4
Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis.干细胞治疗对脊髓小脑共济失调功能恢复的影响：系统评价与荟萃分析
Cerebellum Ataxias. 2021 Feb 25;8(1):8. doi: 10.1186/s40673-021-00130-8.
5
Human ES-derived MSCs correct TNF-α-mediated alterations in a blood-brain barrier model.人胚胎干细胞来源的间充质干细胞纠正 TNF-α 介导的血脑屏障模型改变。
Fluids Barriers CNS. 2019 Jul 1;16(1):18. doi: 10.1186/s12987-019-0138-5.
6
Mesenchymal stem cells in dogs with demyelinating leukoencephalitis as an experimental model of multiple sclerosis.以脱髓鞘性白质脑炎犬作为多发性硬化实验模型研究间充质干细胞
Heliyon. 2019 Jun 8;5(6):e01857. doi: 10.1016/j.heliyon.2019.e01857. eCollection 2019 Jun.
7
Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine.命名和异质性：对再生医学中使用间充质干细胞的影响。
Regen Med. 2019 Jun;14(6):595-611. doi: 10.2217/rme-2018-0145. Epub 2019 May 22.
8
Transcriptional Profiling of Mesenchymal Stem Cells Identifies Distinct Neuroimmune Pathways Altered by CNS Disease.间充质干细胞的转录谱分析确定了中枢神经系统疾病改变的不同神经免疫途径。
Int J Stem Cells. 2018 May 30;11(1):48-60. doi: 10.15283/ijsc17062.
9
Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis.间充质干细胞培养扩增用于多发性硬化症I期临床试验的可行性。
Mult Scler J Exp Transl Clin. 2018 Mar 26;4(1):2055217318765288. doi: 10.1177/2055217318765288. eCollection 2018 Jan-Mar.
10
Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders.增强移植间充质干细胞旁分泌效力的策略在难治性新生儿疾病中的应用。
Pediatr Res. 2018 Jan;83(1-2):214-222. doi: 10.1038/pr.2017.249. Epub 2017 Nov 1.
本文引用的文献
1
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.在 CAMMS223 临床试验的 5 年随访中，阿仑单抗比干扰素β-1a 更有效。
Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.
2
Current Immunotherapy of Multiple Sclerosis and Future Challenges: Relevance of Immune-mediated Repair.
Curr Pharm Biotechnol. 2012 Feb 14.
3
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.自体间充质干细胞治疗继发进展型多发性硬化症：一项开放标签 2a 期概念验证研究。
Lancet Neurol. 2012 Feb;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2. Epub 2012 Jan 10.
4
Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury.间质干细胞移植促进了脊髓损伤后巨噬细胞激活的替代途径和功能恢复。
J Neurotrauma. 2012 May 20;29(8):1614-25. doi: 10.1089/neu.2011.2109. Epub 2012 Apr 18.
5
Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.多能性、骨髓来源的基质细胞在宿主防御中的新作用。
Blood. 2012 Feb 23;119(8):1801-9. doi: 10.1182/blood-2011-10-384354. Epub 2012 Jan 6.
6
The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies.
Front Biosci (Elite Ed). 2012 Jan 1;4(3):824-37. doi: 10.2741/E422.
7
Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α.基于间充质干细胞的组织再生受受体 T 淋巴细胞通过 IFN-γ 和 TNF-α 调控。
Nat Med. 2011 Nov 20;17(12):1594-601. doi: 10.1038/nm.2542.
8
TLR-dependent T cell activation in autoimmunity.TLR 依赖性 T 细胞在自身免疫中的活化。
Nat Rev Immunol. 2011 Nov 18;11(12):807-22. doi: 10.1038/nri3095.
9
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.间充质干细胞通过树突状细胞损害体内 T 细胞的初始激活。
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17384-9. doi: 10.1073/pnas.1103650108. Epub 2011 Sep 29.
10
Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management.靶向 Toll 样受体：多发性硬化症治疗的新兴疗法。
J Neuroimmunol. 2011 Oct 28;239(1-2):1-12. doi: 10.1016/j.jneuroim.2011.08.010. Epub 2011 Sep 1.
Zotero 插件